crv431
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 25, 2018 (NCT03596697)
Timeline
Indications
Mechanism of action
- Cyclophilin AINHIBITOR
PPIA inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)CCCCCCNC(C)=O)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)N(C)C1=O- Mol. weight
- 1303.78 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297487 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05737433 | Early Phase 1 (Phase 1) | Mar 1, 2023 | Hepion Pharmaceuticals, Inc., Quotient |
| NCT05402371 | Phase 2 | Oct 15, 2022 | Hepion Pharmaceuticals, Inc., Pinnacle Research Group |
| NCT05461105 | Phase 2 | Sep 15, 2022 | Hepion Pharmaceuticals, Inc. |
| NCT04480710 | Phase 2 | Jun 23, 2020 | Hepion Pharmaceuticals, Inc. |
| NCT03596697 | Phase 1 | Jun 25, 2018 | Hepion Pharmaceuticals |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hepion Pharmaceuticals, Inc. | For profit | 4 | 4 | 2 | 2020 |
| Hepion Pharmaceuticals | For profit | 1 | 1 | 1 | 2018 |
| Pinnacle Research Group | For profit | 1 | 0 | 1 | 2022 |
| Quotient | For profit | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1